Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey: "QOL Survey in Premenopausal Breast Cancer Patients"
Overview
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Takeda
- Enrollment
- 2,816
- Primary Endpoint
- QOL-ACD Total and Subscale Score at Week 12
Overview
Brief Summary
The purpose of this survey is to examine the effect on quality of life (QOL) improvement and convenience of switching to leuprorelin acetate 3 months depot 11.25 milligram (mg) injection kit (Leuplin SR 11.25 mg injection kit) from a 4-week adjuvant therapy with a luteinizing hormone-releasing hormone analog (LH-RHa) 1 month depot over 48 weeks in premenopausal breast cancer participants in daily medical practice. Influence of condition of estrogen receptor expression on the efficacy and safety of leuprorelin acetate SR 11.25 mg injection kit was also evaluated.
Detailed Description
This survey was designed to examine the effect on QOL improvement and convenience of switching to leuprorelin acetate 3 month depot 11.25 mg injection kit (Leuplin SR 11.25 mg injection kit) from a 4-week adjuvant therapy with a LH-RHa 1 month depot over 48 weeks in premenopausal breast cancer participants in daily medical practice, as well as to evaluate the influence of condition of estrogen receptor expression on the efficacy and safety of leuprorelin acetate SR 11.25 mg injection kit .
For adults, leuprorelin acetate SR 11.25 mg injection kit (Leuplin SR 11.25 mg Injection Kit) is usually administered subcutaneously once every 12 weeks. Prior to injection, the plunger rod of the syringe is pushed upward with the needle pointed upward, allowing the entire suspension fluid contained to be transferred to the powder. The powder is then fully suspended in the fluid while ensuring that bubbles are not generated.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Premenopausal breast cancer participants who meet all the following criteria are to be enrolled in the surveillance:
- •Participants who received 4 weeks of treatment with a repository LH-RHa preparation within 1 week prior to administration of Leuplin SR 11.25 mg Injection Kit.
- •Participants receiving Leuplin SR 11.25 mg Injection Kit as adjuvant therapy.
- •Participants with performance status grade of 0 or
- •Participants who answered all of the questions on the "QOL check sheet (I)" at the start (Week 0) of treatment with Leuplin SR 11.25 mg Injection Kit.
Exclusion Criteria
- •Participants who meet any of the following criteria are to be excluded from the surveillance:
- •Participants with a history of hypersensitivity to ingredient(s) in Leuplin SR 11.25 mg Injection Kit or synthetic derivatives of luteinizing hormone-releasing hormone (LH-RH) or LH-RH.
- •Pregnant women, possibly pregnant women, and nursing mothers.
- •Participants with advanced (T4 or M1 according to the TNM classification \[General Rules for Clinical and Pathological Recording of Breast Cancer: 16th edition\]) or recurrent breast cancer.
Arms & Interventions
Leuprorelin Acetate
Subcutaneous administration of leuprorelin acetate 11.25 mg once every 12 weeks
Intervention: Leuprorelin Acetate (Drug)
Outcomes
Primary Outcomes
QOL-ACD Total and Subscale Score at Week 12
Time Frame: Week 12
QOL-ACD score is a score used for cancer participants treated with anti-cancer drug and is a 22-item self-reported instrument assessing differences in symptom severity and health-related QOL. It includes 4 subscale domains: Daily Activities, Physical Condition, Social Activities, Mental and Psychological Status. Total and subscale scores are calculated as sum of items within each subscale: Daily Activity (items 1-6), Physical Condition (7-11), Psychological Condition (12-16), Social Attitude (17-21) and total (1-22). Face scale:5-point score for 1 item (22). Participants answer each question on a 5-point scale (1: not at all \[worst response\] to 5: very much \[best response\]). Score range for total score is 22 to 110 and subscale score range for daily activity is 6 to 30, and for physical condition, psychological condition, and social attitude is 5 to 25. Less total/subscale scores reflect greater symptom severity and symptom impact on health-related QOL.
Score of QOL-ACD-B at Week 48
Time Frame: Week 48
QOL-ACD-B is a part of QOL-ACD (using questionnaire items 1 to 18). QOL-ACD is a score used for cancer participants treated with anti-cancer drug and is a 22-item self-reported instrument assessing differences in symptom severity and health-related QOL. Participants answer each question on a 5-point scale (1: not at all \[worst response\] to 5: very much \[best response\]). Total score for QOL-ACD-B is calculated as a sum of 18 items, score range: 18 to 90 where less scores reflect greater symptom severity and symptom impact on health-related quality of life. Means and standard deviations were calculated for the total score and score of each subscale from questionnaire items 1 to 18.
Score of QOL-ACD-B Items 19, 20 and 21 at Baseline
Time Frame: Baseline
QOL-ACD-B is a part of QOL-ACD (using questionnaire items 1 to 18). For questionnaire item 19 (Did you feel inferior to your child when you interact with him/her? \[due to the impact of illness and treatment\]), item 20 (Did you worry about child rearing? \[due to the impact of illness and treatment\]), and item 21 (Do you worry about pregnancy or delivery? \[due to the impact of illness and treatment\]), the calculation was based on the score of each item. Each item was scored on a 5-point scale, where 1 was the worst response and 5 was the best.
Score of QOL-ACD-B Items 19, 20 and 21 at Week 12
Time Frame: Week 12
QOL-ACD-B is a part of QOL-ACD (using questionnaire items 1 to 18). For questionnaire item 19 (Did you feel inferior to your child when you interact with him/her? \[due to the impact of illness and treatment\]), item 20 (Did you worry about child rearing? \[due to the impact of illness and treatment\]), and item 21 (Do you worry about pregnancy or delivery? \[due to the impact of illness and treatment\]), the calculation was based on the score of each item. Each item was scored on a 5-point scale, where 1 was the worst response and 5 was the best.
Score of QOL-ACD-B Items 19, 20 and 21 at Week 48
Time Frame: Week 48
QOL-ACD-B is a part of QOL-ACD (using questionnaire items 1 to 18). For questionnaire item 19 (Did you feel inferior to your child when you interact with him/her? \[due to the impact of illness and treatment\]), item 20 (Did you worry about child rearing? \[due to the impact of illness and treatment\]), and item 21 (Do you worry about pregnancy or delivery? \[due to the impact of illness and treatment\]), the calculation was based on the score of each item. Each item was scored on a 5-point scale, where 1 was the worst response and 5 was the best.
Quality of Life Questionnaire for Cancer Patients Treated With Anticancer Drugs (QOL-ACD) Total and Subscale Score at Baseline
Time Frame: Baseline
QOL-ACD score is a score used for cancer participants treated with anti-cancer drug and is a 22-item self-reported instrument assessing differences in symptom severity and health-related QOL. It includes 4 subscale domains: Daily Activities, Physical Condition, Social Activities, Mental and Psychological Status. Total and subscale scores are calculated as sum of items within each subscale: Daily Activity (items 1-6), Physical Condition (7-11), Psychological Condition (12-16), Social Attitude (17-21) and total (1-22). Face scale: 5-point score for 1 item (22). Participants answer each question on a 5-point scale (1: not at all \[worst response\] to 5: very much \[best response\]). Score range for total score is 22 to 110 and subscale score range for daily activity is 6 to 30, and for physical condition, psychological condition, and social attitude is 5 to 25. Less total/subscale scores reflect greater symptom severity and symptom impact on health-related QOL.
QOL-ACD Total and Subscale Score at Week 48
Time Frame: Week 48
QOL-ACD score is a score used for cancer participants treated with anti-cancer drug and is a 22-item self-reported instrument assessing differences in symptom severity and health-related QOL. It includes 4 subscale domains: Daily Activities, Physical Condition, Social Activities, Mental and Psychological Status. Total and subscale scores are calculated as sum of items within each subscale: Daily Activity (items 1-6), Physical Condition (7-11), Psychological Condition (12-16), Social Attitude (17-21) and total (1-22). Face scale: 5-point score for 1 item (22). Participants answer each question on a 5-point scale (1: not at all \[worst response\] to 5: very much \[best response\]). Score range for total score is 22 to 110 and subscale score range for daily activity is 6 to 30, and for physical condition, psychological condition, and social attitude is 5 to 25. Less total/subscale scores reflect greater symptom severity and symptom impact on health-related QOL.
QOL-ACD Breast (QOL-ACD-B) Score at Baseline
Time Frame: Baseline
QOL-ACD-B is a part of QOL-ACD (using questionnaire items 1 to 18). QOL-ACD is a score used for cancer participants treated with anti-cancer drug and is a 22-item self-reported instrument assessing differences in symptom severity and health-related QOL. Participants answer each question on a 5-point scale (1: not at all \[worst response\] to 5: very much \[best response\]). Total score was calculated over score range 0-100 for item 1 to 18 as ((a sum of 18 items)/18-1)\*25). Score for physical condition and pain was calculated over score range 0-100 for item 1 to 6 as ((a sum of 6 items)/6-1)\*25)). Score for health-care and illness satisfaction was calculated over score range 0-100 for item 7 to 10 as ((a sum of 4 items)/4-1)\*25)), where less scores reflect greater symptom severity and symptom impact on health-related quality of life. Means and standard deviations were calculated for the total score and score of each subscale from questionnaire items 1 to 18.
Score of QOL-ACD-B at Week 12
Time Frame: Week 12
QOL-ACD-B is a part of QOL-ACD (using questionnaire items 1 to 18). QOL-ACD is a score used for cancer participants treated with anti-cancer drug and is a 22-item self-reported instrument assessing differences in symptom severity and health-related QOL. Participants answer each question on a 5-point scale (1: not at all \[worst response\] to 5: very much \[best response\]). Total score for QOL-ACD-B is calculated as a sum of 18 items, score range: 18 to 90 where less scores reflect greater symptom severity and symptom impact on health-related quality of life. Means and standard deviations were calculated for the total score and score of each subscale from questionnaire items 1 to 18.
Secondary Outcomes
- Percentage of Participants Who Felt Relief From Physical and Emotional Burden(Week 48)
- Percentage of Participants With Relief From Financial Burden Due to the Change in Medicinal Agents(Week 48)
- Percentage of Participants With Change in Adverse Drug Reactions Due to the Change in Medicinal Agents(Week 48)
- Percentage of Participants With Positive Change in Agents(Week 48)
- Percentage of Participants With Reduction in Frequency of Medical Visits Due to Change in Medicinal Agents(Week 48)
- Number of Participants Reporting One or More Adverse Drug Reactions(Baseline up to Week 48)
- Percentage of Participants Who Worried About the Effect of the Medicinal Agent(Week 48)
- Percentage of Participants With Change in Pain at the Time of Injection Due to the Change in Medicinal Agents(Week 48)
- Number of Participants Reporting One or More Serious Adverse Drug Reactions(Baseline up to Week 48)